Enhanced cutaneous radiation effects following high-dose busulfan therapy

G. Vassal; O. Hartmann; J. L. Habrand; J. L. Pico; J. Lemerle

doi:10.1007/BF00273529

Enhanced cutaneous radiation effects following high-dose busulfan therapy

G. Vassal, O. Hartmann, J. L. Habrand, J. L. Pico, J. Lemerle

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

5 Citations (Scopus)

Résumé

Fifteen patients received irradiation after combined chemotherapy with high-dose busulfan followed by autologous or allogeneic bone marrow transplantation. Of nine patients irradiated between day 30 and day 70 after their engraftment, seven developed an increased radiation response in the skin: four showed enhanced reactions during irradiation, and three had a total or severe definitive alopecia more than 16 months after CNS irradiation. Six patients were irradiated after day 70; they had either normal reactions or none at all within the cutaneous radiation portals. The possibility that busulfan might be a radiosensitizer is raised.

langue originale	Anglais
Pages (de - à)	117-118
Nombre de pages	2
journal	Cancer Chemotherapy and Pharmacology
Volume	23
Numéro de publication	2
Les DOIs	https://doi.org/10.1007/BF00273529
état	Publié - 1 févr. 1989

Accès au document

10.1007/BF00273529

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{b4a49c2d36f7487490b43679db8142d8,

title = "Enhanced cutaneous radiation effects following high-dose busulfan therapy",

abstract = "Fifteen patients received irradiation after combined chemotherapy with high-dose busulfan followed by autologous or allogeneic bone marrow transplantation. Of nine patients irradiated between day 30 and day 70 after their engraftment, seven developed an increased radiation response in the skin: four showed enhanced reactions during irradiation, and three had a total or severe definitive alopecia more than 16 months after CNS irradiation. Six patients were irradiated after day 70; they had either normal reactions or none at all within the cutaneous radiation portals. The possibility that busulfan might be a radiosensitizer is raised.",

author = "G. Vassal and O. Hartmann and Habrand, {J. L.} and Pico, {J. L.} and J. Lemerle",

year = "1989",

month = feb,

day = "1",

doi = "10.1007/BF00273529",

language = "English",

volume = "23",

pages = "117--118",

journal = "Cancer Chemotherapy and Pharmacology",

issn = "0344-5704",

number = "2",

}

TY - JOUR

T1 - Enhanced cutaneous radiation effects following high-dose busulfan therapy

AU - Vassal, G.

AU - Hartmann, O.

AU - Habrand, J. L.

AU - Pico, J. L.

AU - Lemerle, J.

PY - 1989/2/1

Y1 - 1989/2/1

N2 - Fifteen patients received irradiation after combined chemotherapy with high-dose busulfan followed by autologous or allogeneic bone marrow transplantation. Of nine patients irradiated between day 30 and day 70 after their engraftment, seven developed an increased radiation response in the skin: four showed enhanced reactions during irradiation, and three had a total or severe definitive alopecia more than 16 months after CNS irradiation. Six patients were irradiated after day 70; they had either normal reactions or none at all within the cutaneous radiation portals. The possibility that busulfan might be a radiosensitizer is raised.

AB - Fifteen patients received irradiation after combined chemotherapy with high-dose busulfan followed by autologous or allogeneic bone marrow transplantation. Of nine patients irradiated between day 30 and day 70 after their engraftment, seven developed an increased radiation response in the skin: four showed enhanced reactions during irradiation, and three had a total or severe definitive alopecia more than 16 months after CNS irradiation. Six patients were irradiated after day 70; they had either normal reactions or none at all within the cutaneous radiation portals. The possibility that busulfan might be a radiosensitizer is raised.

UR - http://www.scopus.com/inward/record.url?scp=0024216113&partnerID=8YFLogxK

U2 - 10.1007/BF00273529

DO - 10.1007/BF00273529

M3 - Article

C2 - 2910507

AN - SCOPUS:0024216113

SN - 0344-5704

VL - 23

SP - 117

EP - 118

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

IS - 2

ER -